Altman Peter purchased $2K of BCDA

Altman Peter (President and CEO) purchased 2,300 shares of BioCardia, Inc. (BCDA) at an average of $0.89 ($0.85–$0.96) across 2 trades over 2026-06-17 to 2026-06-18.

Original reporting
SEC EDGAR · Altman Peter
Published Jun 22, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

The only new information is the insider’s open-market purchase details and the updated post-transaction share count. The text does not include any operational update, guidance, or regulatory/clinical catalyst.

02

Market read

Traders may note the insider buy as a small positive sentiment datapoint, but it is not a standalone fundamental catalyst in the provided text.

03

What to watch

The filing notes no 10b5-1 plan, but it also provides no reason for the purchase, and the price range suggests execution across two days rather than a single conviction entry.

Relevance 4/10Novelty 4/10Timing: Form 4 filed June 22, covering trades on June 17-18.

Background

This is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA) by its President and CEO, Peter Altman.

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Peter Altman bought 2,300 shares in open-market trades at $0.8500 to $0.9600, per a new Form 4 filed June 22.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and fade unless followed by additional fundamental news.

Evidence & confidence

Form 4 confirms the transaction occurred and was newly disclosed, but the total value (~$2.0k) is modest and there is no accompanying guidance, contract, or operational update in the text.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax planning, liquidity needs, or pre-planned behavior) and may not signal improved fundamentals, especially at small dollar size.

Key entities

  • BioCardia, Inc.

    Subject of the Form 4 insider transaction disclosure (BCDA).

  • Peter Altman

    President and CEO who reported the open-market purchase of 2,300 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.